Arine, a San Francisco-based AI-driven platform that optimizes medication management, reduces costs, and improves outcomes for health plans and providers, announced that it closed $11 million in an oversubscribed Series A.
The round was co-led by 111° West Capital Partners and Katalyst Ventures, with strategic investments from Magellan Health Inc. and SCAN Group.
Arine plans to use the latest round of funding to rapidly scale its team and its technology platform from the 5.5M lives actively managed today.
Company: Arine, Inc.
Round: Series A
Funding Month: October 2021
Lead Investors: 111° West Capital Partners and Katalyst Ventures
Additional Investors: Magellan Health Inc. and SCAN Group
Company Website: https://www.arine.io/
Software Category: AI-driven platform- medication management
About the Company: Arine, an AI-driven platform that optimizes medication management, reduces costs, and improves outcomes for health plans and providers. Arine optimizes medication therapy and treatment plans – saving 1 in every six healthcare dollars spent. Arine’s approach meets patients where they are, creates a whole picture of each patient based on clinical, social, and behavioral data, and enables clinicians to provide personalized care. The platform’s thousands of algorithms intake and analyze multi-source data to recommend just-in-time clinical interventions for each patient at their point of need. These timely interventions reduce the total cost of care and drive a significant ROI for healthcare organizations.